China Resources Medical Holdings Full Year 2024 Earnings: Misses Expectations

China Resources Medical Holdings (HKG:1515) Full Year 2024 Results

Key Financial Results

• Revenue: CN¥9.85b (down 2.5% from FY 2023).
• Net income: CN¥565.9m (up 120% from FY 2023).
• Profit margin: 5.7% (up from 2.5% in FY 2023). The increase in margin was driven by lower expenses.
• EPS: CN¥0.45 (up from CN¥0.20 in FY 2023).

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10bn in marketcap - there is still time to get in early.

All figures shown in the chart above are for the trailing 12 month (TTM) period

China Resources Medical Holdings Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 4.3%. Earnings per share (EPS) also missed analyst estimates by 19%.

The primary driver behind last 12 months revenue was the Hospital Business segment contributing a total revenue of CN¥9.18b (93% of total revenue). Notably, cost of sales worth CN¥8.04b amounted to 82% of total revenue thereby underscoring the impact on earnings. The largest operating expense was General & Administrative costs, amounting to CN¥1.05b (84% of total expenses). Explore how 1515's revenue and expenses shape its earnings.

Looking ahead, revenue is forecast to grow 3.6% p.a. on average during the next 3 years, compared to a 6.9% growth forecast for the Healthcare industry in Hong Kong.

Performance of the Hong Kong Healthcare industry.

The company's shares are down 9.5% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for China Resources Medical Holdings that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.